DE69012591D1 - Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. - Google Patents

Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.

Info

Publication number
DE69012591D1
DE69012591D1 DE69012591T DE69012591T DE69012591D1 DE 69012591 D1 DE69012591 D1 DE 69012591D1 DE 69012591 T DE69012591 T DE 69012591T DE 69012591 T DE69012591 T DE 69012591T DE 69012591 D1 DE69012591 D1 DE 69012591D1
Authority
DE
Germany
Prior art keywords
nicotine
treatment
dose
respond
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69012591T
Other languages
English (en)
Other versions
DE69012591T2 (de
Inventor
Joseph G Masterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11005849&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69012591(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE69012591D1 publication Critical patent/DE69012591D1/de
Publication of DE69012591T2 publication Critical patent/DE69012591T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69012591T 1989-01-06 1990-01-05 Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. Revoked DE69012591T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE4389A IE62662B1 (en) 1989-01-06 1989-01-06 Use of nicotine in the treatment of conditions susceptible to said treatment

Publications (2)

Publication Number Publication Date
DE69012591D1 true DE69012591D1 (de) 1994-10-27
DE69012591T2 DE69012591T2 (de) 1995-04-20

Family

ID=11005849

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69012591T Revoked DE69012591T2 (de) 1989-01-06 1990-01-05 Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.

Country Status (8)

Country Link
US (1) US5069904A (de)
EP (1) EP0377520B1 (de)
JP (1) JP2886231B2 (de)
AT (1) ATE111733T1 (de)
DE (1) DE69012591T2 (de)
DK (1) DK0377520T3 (de)
ES (1) ES2060941T3 (de)
IE (1) IE62662B1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156847A (en) * 1990-09-20 1992-10-20 Walter H. Lewis Wound-healing composition
KR0137003B1 (ko) * 1991-03-01 1998-04-25 카렌 에이. 홀브루크 신경계 퇴행성 질환치료용 니코틴 아날로그의 용도
US5242934A (en) * 1992-03-02 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5288872A (en) * 1992-03-13 1994-02-22 Wake Forest University Compounds for treatment of neurodegenerative diseases
US5227385A (en) * 1992-03-13 1993-07-13 Wake Forest University Method for treatment of neurodegenerative diseases
US5187169A (en) * 1992-04-10 1993-02-16 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) * 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5214060A (en) * 1992-04-10 1993-05-25 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232932A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5242916A (en) * 1992-07-07 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5248690A (en) * 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
EP0656771A4 (de) * 1992-08-25 1996-07-31 Cygnus Therapeutic Systems Vorrichtung zur transdermalen medikamentenabgabe.
US6602892B1 (en) 1993-06-10 2003-08-05 David P. L. Sachs Methods for nicotine replacement dosage determination
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5474782A (en) * 1994-05-20 1995-12-12 Woundfast Pharmaceuticals, Inc. Wound-healing composition and method
AU4610896A (en) * 1995-01-06 1996-07-24 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AU2340397A (en) * 1996-03-21 1997-10-10 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5960956A (en) * 1997-02-19 1999-10-05 St. Jude Medical, Inc. Storage container
AU8562998A (en) * 1997-08-12 1999-03-01 Takeda Chemical Industries Ltd. Idebenone-containing preparation for percutaneous administration
US5932617A (en) * 1998-02-06 1999-08-03 Woundfast Pharmaceuticals Inc. Wound-treating composition and method
GB9805559D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AT409219B (de) * 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln
US6716589B2 (en) * 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
ATE398461T1 (de) 2001-02-13 2008-07-15 Us Gov Sec Army Impstoffe zur transkutanen immunisierung gegen reisediarrhö
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
KR20050096922A (ko) 2002-12-20 2005-10-06 니코노범 에이비 물리적 및 화학적으로 안정된 니코틴 함유 입자물질
EP1802258A4 (de) 2004-09-13 2015-09-23 Chrono Therapeutics Inc Biosynchrone transdermale arzneiabgabe
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
GB2448224B (en) * 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
EP2197430A2 (de) * 2007-09-18 2010-06-23 NicoNovum AB Stabile kaugummizusammensetzungen mit maltitol und schneller freisetzung von nikotin
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
EP2706854A4 (de) * 2011-05-09 2014-12-03 Envivo Pharmaceuticals Inc Behandlung kognitiver störungen mit bestimmten alpha-7-nikotinsäurerezeptoragonisten in kombination mit nikotin
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
EP3154530B1 (de) * 2014-06-10 2018-04-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Nanopartikulärer komplex aus nicotin und ceriumoxid und dessen verwendung
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
US20210255202A1 (en) 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device

Also Published As

Publication number Publication date
US5069904A (en) 1991-12-03
EP0377520B1 (de) 1994-09-21
ATE111733T1 (de) 1994-10-15
DE69012591T2 (de) 1995-04-20
JPH02225414A (ja) 1990-09-07
ES2060941T3 (es) 1994-12-01
JP2886231B2 (ja) 1999-04-26
EP0377520A2 (de) 1990-07-11
IE62662B1 (en) 1995-02-22
DK0377520T3 (da) 1994-10-17
EP0377520A3 (de) 1991-07-17

Similar Documents

Publication Publication Date Title
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
Fanget et al. Nocturnal plasma melatonin levels in schizophrenic patients.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ATE64530T1 (de) Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE69331605T2 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
ATE143260T1 (de) Verwendung von (s)-isofluran und (s)-desfluran zur anästhesie sowie entsprechende arzneimittelzubereitungen
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE59307982D1 (de) Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
DE69516110T2 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
NO169539C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive kondenserte diazepinoner
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
Thorner Multiple neuritis from therapy with hematoporphyrin hydrochloride
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
Jupp et al. Hypnotic susceptibility and depth: Predictors of outcome in a weight control therapy.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation